EUVIMEDSkopri EUVIMED
Crossref

Treatment rates and factors associated with direct‐acting antiviral therapy for insured patients with hepatitis C‐related hepatocellular carcinoma – A real‐world nationwide study

Leslie Y Kam iD, Yee Hui Yeo iD, Fanpu Ji iD, Linda Henry, Ramsey Cheung, Mindie H Nguyen iD

Alimentary Pharmacology & Therapeutics · 2024

DOI: 10.1111/apt.17794 ↗

At a glance

Journal article in Alimentary Pharmacology & Therapeutics, 2024. Written by Leslie Y Kam and 5 co-authors. Institution: Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA. Major MEDLINE topics: Carcinoma, Hepatocellular, Liver Neoplasms, Hepatitis C, Chronic, Hepatitis C. Cited 9 times so far (Crossref); 45 references. Funded by: NCATS NIH HHS.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Since the inception of the interferon‐free direct‐acting antiviral agents (DAAs) for hepatitis C virus (HCV) infection, guidelines as to who should receive this potentially curative treatment have evolved. Treatment with DAAs is now considered for all patients except for those considered moribund.

Aim

To determine the DAA treatment rate for patients with HCV‐related hepatocellular carcinoma (HCC).

Methods

This was a retrospective study from January 2015 to March 2021 of a national sample of privately insured patients with HCV‐related HCC using Optum's Clinformatics® Data Mart (CDM) Database – a large, de‐identified, adjudicated claims database.

Results

We identified 3922 patients with HCV‐related HCC: 922 (23.5%) received DAA. Compared to untreated patients, DAA‐treated patients were younger (65.2 ± 7.5 vs. 66.4 ± 7.5 years, p < 0.001), more frequently saw a gastroenterology/infectious disease (GI/ID) physician (41.2% vs. 34.2%), and had decompensated cirrhosis (56% vs. 53%, p = 0.001). In multivariable analysis, younger age (HR: 0.98, 95% CI: 0.97–0.99, p < 0.001), GI/ID care (HR: 3.06, 95% CI: 2.13–4.51, p < 0.001), and having cirrhosis (compensated: HR: 1.60, 95% CI: 1.18–2.21, p = 0.003; decompensated: HR: 1.45, 95% CI: 1.07–1.98, p = 0.02) were associated with receiving DAA treatment, but not sex, race, or ethnicity. DAA‐treated patients had significantly higher 5‐year survival than untreated patients (47.2% vs. 35.2%, p < 0.001). Following adjustment for age, sex, race/ethnicity, Charlson Comorbidity Index, and HCC treatment, receiving DAA treatment was associated with lower mortality (aHR: 0.61, 95% CI: 0.53–0.69, p < 0.001).

Conclusion

DAA treatment remains underutilised in insured patients with HCV‐related HCC; fewer than one in four patients received treatment. Seeing a specialist and having decompensated cirrhosis were predictors for DAA treatment; additional efforts are needed to increase awareness of HCV treatment.

Subjects

MeSH terms (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHepatitis C, ChronicHepatitis CHumansAntiviral AgentsRetrospective StudiesLiver CirrhosisHepacivirus

Author keywords

hepatitisliver cancermortalitytreatment

Substances

Antiviral Agents

Authors and institutions

  • Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA.
  • Karsh Division of Gastroenterology and Hepatology, Cedars Sinai Medical Center, Los Angeles, California, USA.
  • Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
  • Division of Gastroenterology and Hepatology, Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA.
  • Department of Epidemiology and Population Health, Stanford University Medical Center, Palo Alto, California, USA.

ORCID profiles: Leslie Y Kam, Yee Hui Yeo, Fanpu Ji, Mindie H Nguyen

Funding

  • NCATS NIH HHS

Cite

APA

Kam, L. Y., Yeo, Y. H., Ji, F., Henry, L., Cheung, R., & Nguyen, M. H. (2024). Treatment rates and factors associated with direct‐acting antiviral therapy for insured patients with hepatitis C‐related hepatocellular carcinoma – A real‐world nationwide study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17794

Vancouver

Kam LY, Yeo YH, Ji F, Henry L, Cheung R, Nguyen MH. Treatment rates and factors associated with direct‐acting antiviral therapy for insured patients with hepatitis C‐related hepatocellular carcinoma – A real‐world nationwide study. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.17794

BibTeX
@article{Kam2024,
  author = {Kam, Leslie Y and Yeo, Yee Hui and Ji, Fanpu and Henry, Linda and Cheung, Ramsey and Nguyen, Mindie H},
  title = {Treatment rates and factors associated with direct‐acting antiviral therapy for insured patients with hepatitis C‐related hepatocellular carcinoma – A real‐world nationwide study},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1111/apt.17794}
}
Start for free →